Board

 

Joel B. Braunstein, MD, MBA
Co-Founder President and CEO

Dr. Braunstein is Co-Founder and CEO of C₂N Diagnostics and has led the company's growth and commercial efforts since its inception. Dr. Braunstein has played a senior executive role in numerous emerging life sciences companies since 2004. He received his M.D. with Highest Distinction from Northwestern University Medical School in 1996. Subsequently, he trained in internal medicine at the Brigham and Women’s Hospital, Harvard Medical School, and was a Fellow in Cardiovascular Medicine and Robert Wood Johnson National Clinical Scholar at the Johns Hopkins Medical Institutions. Additionally, he completed an MBA with management and health policy focus and maintained an Assistant Professorship in Cardiology at Johns Hopkins University. In 2010, he was named a Distinguished Alumnus of Johns Hopkins University.

David Holtzman, M.D.
Scientific Co-Founder

David Holtzman is Professor, scientific director of the Hope Center for Neurological Disorders, Principal Investigator of the Knight ADRC, and former Chair of Neurology at Washington University from 2003-2021. Some of his lab’s accomplishments include showing in part how APOE contributes to AD, development of plasma and CSF biomarkers for AD, demonstration that synaptic activity and sleep affect Aβ and tau levels in vivo, describing the effects of APOE, TREM2, and both the innate and adaptive immune response on tau-mediated neurodegeneration. Several of his honors include being a recipient of the Potamkin prize and MetLife award for research on Alzheimer’s disease, Rainwater Prize for outstanding innovation in neurodegenerative disease research, election to the National Academy of Medicine, and being appointed to the National Advisory council of the NINDS and NIA. Holtzman has trained over 70 graduate students, post-doctoral fellows, many of whom have gone on to successful careers in academia and industry.

Randall Bateman, M.D.
Scientific Co-Founder

Dr. Randall Bateman is the Charles F. and Joanne Knight Distinguished Professor of Neurology, Director of the Dominantly Inherited Alzheimer Network (DIAN), Director of the DIAN Trials Unit (DIAN-TU), Principal Investigator of the Bateman Lab, and Director of the Tracy Family Stable Isotope Labeling Quantitation (SILQ) Center for Neurodegenerative Biology. Dr. Bateman’s research focuses on the pathophysiology and development of improved diagnostics and treatments of Alzheimer’s disease. Dr. Bateman treats patients with dementia at the Memory Diagnostic Center of Washington University.

Dr. Bateman’s lab accomplishments include pioneering the central nervous system Stable Isotope Labeling Kinetics (SILK) measurements in humans, which utilizes sub-atomic labeling with stable isotopes to track in vivo protein production and clearance, leading to understanding of the time and kinetic basis of proteins leading to neurodegeneration. His lab has made major contributions to the understanding of the structures and functions of neurodegenerative proteins in pathophysiology of Alzheimer’s disease and other neurodegenerative diseases. Dr. Bateman’s lab discovered the first high-precision blood test for Alzheimer’s disease amyloid plaques in 2017, which is now available to doctors and patients as the first blood test to help diagnose Alzheimer’s disease. His lab has generated the most accurate blood tests for Alzheimer’s disease in head-to-head comparisons, rivaling that of PET and CSF tests, promising to provide accurate diagnosis and the potential for treatment of millions of patients who otherwise would not have access to accurate diagnosis.

Dr. Bateman is a productive innovator with 47 active or pending patents, and co-founder of C2N Diagnostics, which now provides the first high-accuracy blood test for Alzheimer’s disease based on Dr. Bateman’s discoveries at Washington University. Dr. Bateman has established multiple research consortiums, including the DIAN-TU Pharma Consortium, Tau SILK Consortium and the NfL Consortium, which are joint academic and industry collaborations to develop biomarkers useful for tracking and staging disease. Dr. Bateman has established the SILQ Center to further advances in neurodegeneration and aging by utilizing precise measures of neurodegenerative proteins and their production, transport, and clearance in health and disease.

Dr. Bateman has received a number of awards including the Beeson Award for Aging Research, Alzheimer’s Association Zenith Fellow’s Award, Scientific American top innovator, the Glenn Award for Aging Research, the Washington University Chancellor’s Award for Innovation and Entrepreneurship, the MetLife Foundation Award for Medical Research, the Potamkin Prize, and the CTAD Lifetime Achievement Award in Alzheimer’s Disease Therapeutic Research. He is a member of the American Neurological Association, the American Society for Clinical Investigation Council, and the American Academy of Neurology. He is an elected member of the National Academy of Medicine and the National Academy of Inventors.

Michael Goldblatt, Ph.D., J.D.

Dr. Goldblatt is an active investor in technology startups and consultant to a variety of government agencies, national laboratories and corporations. He brings over 35 years of experience in the areas of biotechnology, product development, and regulatory affairs to C₂N. Michael was Chief Executive Officer of Functional Genetics, a biotechnology company focused on target discovery and antibody therapeutics, until 2013 when its assets were acquired by its collaboration partner Elanco. Michael joined Functional Genetics in 2003, after his appointment as Director of Defense Sciences at the Defense Advanced Research Projects Agency (DARPA), and before that Dr. Goldblatt was the Science and Technology Officer for the McDonald's Corporation with broad responsibilities, including nutrition, product development, food safety and corporate venture capital. Earlier, while at General Foods, he led research efforts in the use of nutrients for pharmaceutical effects and oversaw a variety of regulatory and legal issues. Michael holds dozens of active and pending US patents, and received his J.D. and Ph.D. from the University of California at Davis and a B.A. from Reed College.